The Manufacturers Life Insurance Company Sells 5,197 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

The Manufacturers Life Insurance Company lessened its position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 9.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 47,550 shares of the biotechnology company’s stock after selling 5,197 shares during the period. The Manufacturers Life Insurance Company’s holdings in Aurinia Pharmaceuticals were worth $349,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of AUPH. Price T Rowe Associates Inc. MD lifted its stake in shares of Aurinia Pharmaceuticals by 15.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 38,952 shares of the biotechnology company’s stock worth $196,000 after buying an additional 5,079 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Aurinia Pharmaceuticals by 18.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 488,721 shares of the biotechnology company’s stock worth $2,791,000 after buying an additional 77,510 shares during the last quarter. HighMark Wealth Management LLC lifted its stake in shares of Aurinia Pharmaceuticals by 21.3% during the 2nd quarter. HighMark Wealth Management LLC now owns 91,196 shares of the biotechnology company’s stock worth $521,000 after buying an additional 16,000 shares during the last quarter. Banque Cantonale Vaudoise lifted its stake in shares of Aurinia Pharmaceuticals by 126.6% during the 2nd quarter. Banque Cantonale Vaudoise now owns 9,684 shares of the biotechnology company’s stock worth $55,000 after buying an additional 5,410 shares during the last quarter. Finally, Rhumbline Advisers lifted its stake in shares of Aurinia Pharmaceuticals by 13.3% during the 2nd quarter. Rhumbline Advisers now owns 208,263 shares of the biotechnology company’s stock worth $1,189,000 after buying an additional 24,371 shares during the last quarter. Institutional investors and hedge funds own 36.83% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on AUPH. StockNews.com cut shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Friday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $10.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Monday, September 16th. Finally, HC Wainwright reiterated a “buy” rating and issued a $13.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Friday, September 6th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Aurinia Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $10.00.

Aurinia Pharmaceuticals Price Performance

Shares of NASDAQ:AUPH opened at $9.37 on Monday. The firm has a 50 day moving average of $8.03 and a 200-day moving average of $6.75. The stock has a market capitalization of $1.34 billion, a PE ratio of -62.46 and a beta of 1.41. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17. Aurinia Pharmaceuticals Inc. has a 12 month low of $4.71 and a 12 month high of $10.67.

Insider Activity

In related news, Director Jeffrey Allen Bailey sold 4,557 shares of Aurinia Pharmaceuticals stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $8.43, for a total transaction of $38,415.51. Following the sale, the director now directly owns 13,356 shares of the company’s stock, valued at approximately $112,591.08. The trade was a 25.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 4.30% of the company’s stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.